Drug manufacturer GlaxoSmithKline for the third time this year has announced refunds for overcharging 340B covered entities, this time for purchases of 16 NDCs during Q3 2020.
The U.S. Health Resources and Services Administration (HRSA) posted GSK’s notice to entities yesterday on the Office of Pharmacy Affairs website. The company said it recalculated its 340B ceiling prices for the products as a result of revised Medicaid drug rebate pricing data submitted to the Centers for Medicare & Medicaid Services.
Drug manufacturer GlaxoSmithKline for the third time this year has announced refunds for overcharging 340B covered entities, this time for purchases of 16 NDCs during Q3 2020.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
